Misleading Drug Ads Should Be Subject To Financial Penalties, AARP Says
Executive Summary
Congress should implement financial penalties for misleading drug ads, AARP Executive Director for State & National Initiatives Christopher Hansen said
You may also be interested in...
FDA Preclearance Of DTC Ads Included In Sen. Kennedy Draft Bill
Repeat offenders of direct-to-consumer advertising regulations would be required to submit all future ads to FDA for preclearance under a draft bill sponsored by Sen. Edward Kennedy (D-Mass.)
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials